Efficacy evaluable population

Author: ucrd

August undefined, 2024

WebBrief Summary: A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis. Detailed Description: The primary objective of this prospective controlled study is to evaluate the efficacy and the safety of abaloparatide 80 micrograms (mcg) per day administered subcutaneously (SC) compared to placebo in men with … WebJan 1, 2016 · The Phase 2, 8 mg Tilso/Ipi efficacy evaluable population N=44 (40 with 4 non-evaluable) The Phase 1, 8 mg Tilso/Ipi evaluable population (N=9) Overall …

Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: …

WebA. Muyle, G. Marais, in Encyclopedia of Evolutionary Biology, 2016 Effects on Effective Population Size. With pure selfing, the effective population size, N e, is decreased by … WebApr 1, 2024 · At clinical cut-off (August 31, 2024), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months; 61.2% of patients had a complete ( n = 19) or partial response ( n = 55). calories in 4 oz sweet potato fries

Phase 1A/1B dose-escalation and -expansion study to …

WebApr 14, 2024 · Efficacy evaluable population: Primary and expansion cohorts in all except low grade glioma and multiple myeloma which are primary analysis cohorts. ATC: Among 36 patients, 24 (67%) patients died ... WebDec 10, 2024 · As of the March 2024 data cutoff date, 60 patients with R/R mutant NPM1 or KMT2Ar acute leukemia were efficacy evaluable. In the efficacy evaluable population, the ORR was 53% (32/60) with a... WebMay 3, 2024 · The CR and OR rates will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence interval based on the efficacy evaluable population. Duration of response (DOR) [ Time Frame: Up to 12 months after the CAR-T cell infusion ] Will be assessed among responders. code 2 and the extinguishers

Entrectinib in patients with advanced or metastatic

Updated Integrated Analysis of the Efficacy and Safety of …

WebDec 10, 2024 · In the efficacy evaluable population, the ORR was 53% (32/60) with a CR/CRh rate of 30% (18/60), and 78% (14/18) of patients with CR/CRh attaining minimal residual disease (MRD) negativity. Additional analyses from the trial indicate that at doses which met the protocol defined criteria for a recommended Phase 2 dose (RP2D), the … WebAug 2, 2011 · The intention-to-treat population includes patients who have and have not received the treatment. The efficacy-evaluable population is a subgroup that includes … code 2 play inventorWebThe efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P).The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%. Median progression-free survival was 12.4 months … code 2 super hero tycoon

"WebMay 2, 2024 · Patients received a single infusion of idecabtagene vicleucel, preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Of the 100 … " - Efficacy evaluable population

Efficacy evaluable population

Oral eltanexor treatment of patients with higher-risk …

WebDec 12, 2024 · Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms ... -up. The median overall survival for patients on study was 7.9 months (95% confidence interval, 4.1-not reached). Among evaluable patients, the overall response rate by protocol-defined criteria (complete … Web30 minutes ago · Patient Population: Median age was 63 (range of 31-77); 78% were male; ... 42 pts were evaluable for efficacy, receiving ≥2 treatment cycles (≥8 weeks) with ≥1 post-baseline tumor assessment ...

Did you know?

WebApr 18, 2024 · Consequently, in an analysis according to the ITT principle, the original randomization and the number of patients in the treatment groups remain unchanged, … WebAug 3, 2024 · Of the 20 patients enrolled, 15 patients were evaluable for efficacy, as five 20 mg patients discontinued the study and were thus not evaluable for disease response; ORR for the efficacy-evaluable patients was 53.3% (95% CI 26.6–78.7; Table 1).

WebMay 28, 2024 · Safety population (N = 345) included all pts with NSCLC who received ≥1 selpercatinib dose by data cutoff (30 Mar 2024). Results: In pts with prior treatment (N = … WebIn the primary efficacy population (N=46), the IRC-assessed objective response rate at EOI was 76%, with a CR rate of 61%. The best overall response rate by investigator assessment (INV) was 91%, with a best CR rate of 72%. After a median follow-up of 43.3 months in the efficacy-evaluable population (N=46), median PFS was not reached ( …

WebAug 28, 2024 · Evaluable Population: Includes all randomized participants with a Day 90 MRI. ... The primary efficacy outcome was the incidence of total venous thromboembolism (VTE) up to 14 days. The principal safety outcome was any bleeding, defined as the composite of major, clinically-relevant nonmajor and minimal bleeding. ... WebMay 12, 2024 · Evaluable efficacy. All eligible randomized participants who received all vaccination(s) as randomized within the predefined window and had no other important …

WebSep 29, 2024 · In this population, the mean age was 68.4 years (range, 43-85). The median PSA was 1.27 ng/mL (range, 0.03-134.6), and most patients had a Gleason grade group of 3 (30%). Additional data showed the 18 F-rhPSMA-7.3 detection rate was 88% compared with a correct detection rate of 57%.

WebAug 12, 2024 · The most common RET fusion partners in 23 efficacy-evaluable patients were CCDC6 (26%), KIF5B (26%) and NCOA4 (13%). Overall response rate, the primary endpoint, was 57% (95% confidence... calories in 4 oz sweet potatoWebMar 10, 2024 · A total of 28 patients have enrolled to the trial, 22 of whom were included in the efficacy-evaluable population. Of the 6 remaining patients who were not included in the efficacy analysis, 1... code2vec learning distributedWebDec 1, 2024 · The present TFINE study assessed the efficacy and safety of docetaxel continuation maintenance (DCM) therapy after first-line treatment with different doses of docetaxel plus cisplatin. ... The DCR in the first-line treatment was assessed by a non-inferiority test in the evaluable population, defined as the patients who had at least 1 … calories in 4 oz turkey burger pattyWebDec 11, 2024 · At the data cutoff date for this analysis (May 31, 2024) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77–18·76). 31 (57%; 95% CI 43·2–70·8) of 54 … calories in 4 oz white fishWebSep 1, 2024 · The efficacy-evaluable population included adult patients (aged ≥18 years) with locally advanced or metastatic ROS1 fusion-positive NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at least 12 months' follow-up. All patients had an Eastern Cooperative Oncology Group performance status of 0–2, and ... code 2 player dragon egg tycoonWebApr 25, 2024 · To more accurately evaluate efficacy, the perfect-use analysis was repeated to remove factors that confounded efficacy assessment in ad hoc sensitivity analyses. RESULTS: AMPOWER enrolled 1,384 women; in the efficacy-evaluable population (n=1,003), the perfect-use 7-cycle cumulative pregnancy percentage was 9.99% (95% CI … code 2xp exp update 1.70 beta shuudanWebResults 104 patients were randomized. In the efficacy evaluable population, 42% of XmAb5871-treated subjects reached Day 225 without LOI vs 28.6% of the placebo group (p=0.18) with 40.4% vs 23.1% … calories in 4 oz unsweetened applesauce